Back to search

Aristotle University Of Thessaloniki (AUTH)

Ο ρόλος του μεταγραφικού παράγοντα p63 στη Χρόνια Λεμφοκυτταρική Λευχαιμία

Abstract

dc:description

Chronic Lymphocytic Leukemia (CLL), the most frequent leukemia in Western world, is characterized by a remarkably variable clinical course, likely as a reflection of the underlying biological heterogeneity. The latter is shaped by different cellular mechanisms and factors contributing to disease pathogenesis. Recent evidence has highlighted that the TA-isoform of the p63 transcription factor (TAp63) affects CLL cells viability and likely contributes to clinical aggressiveness, albeit in a hitherto elusive way. In CLL, TAp63 expression, is modulated by both immune signaling and epigenetic modifications. In activated normal B cells, the TAp63 transcription factor activates the BCL2 gene, participating in the NF-κB/TAp63/BCL2 anti-apoptotic pathway. On these grounds, here, we sought to further understand and define the role of TAp63 in the pathophysiology of CLL and also to explore molecular links between TAp63 and BCL2 in CLL cells.First, we performed TAp63 mRNA expression analysis in distinct subgoups of patients and found that elevated TAp63 expression levels are linked with adverse prognostic features and clinical outcomes, including shorter time-to-first treatment and overall survival. Moreover, we analyzed TAp63 mRNA expression in longitudinal samples of CLL cases treated with either chemoimmunotherapy or signaling inhibitors to report that TAp63 is overexpressed in relapse/refractory disease. Next, we explored molecular links between TAp63 and BCL2 in CLL cells and documented a strong correlation at both the protein and the mRNA levels, alluding to the potential prosurvival role of TAp63 in the following settings: a) both stimulated and unstimulated primary CLL cells; and, b) primary CLL cells after TAp63 downregulation by RNA interference. This finding was further supported by inducible downregulation of TAp63 expression in the MEC1 CLL cell line using CRISPR, which resulted in downregulation of BCL2 expression. In order to elucidate the transcriptional network of TΑp63, we performed ChIP-sequencing and identified high-confidence TAp63 binding regions in genes implicated in disease pathogenesis that regulate cellular processes necessary for cell survival. Furthermore, we examined whether BCL2 might constitute a transcriptional target of TAp63 and reported a significant binding profile of TAp63 in the BCL2 gene locus, across a genomic region previously characterized as a super-enhancer in CLL. Finally, we found that up-regulated TAp63 expression levels render CLL cells less responsive to apoptosis induction with the BCL2 inhibitor, venetoclax. Collectively, TAp63 emerges as a positive modulator of BCL2, hence contributing to the anti-apoptotic phenotype that underlies clinical aggressiveness and treatment resistance in CLL.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Laidou, Stamatia
  • Λαΐδου, Σταματία

Subjects

dc:subject × 15

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/51992

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Laidou, Stamatia; Λαΐδου, Σταματία. Ο ρόλος του μεταγραφικού παράγοντα p63 στη Χρόνια Λεμφοκυτταρική Λευχαιμία. Aristotle University Of Thessaloniki (AUTH), 2022. http://hdl.handle.net/10442/hedi/51992